Condition (MeSH)
Cherubism
ClinicalTrials.gov lists 2 trials for Cherubism or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section
3 sections measured, none recorded · 1 not measured yet · 1 not computed
2 of the 2 trials are tagged with Cherubism itself; the rest are tagged with a narrower condition beneath it.
When did Cherubism trials start? (2)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
| Year | Trials started |
|---|---|
| 2013 | 1 |
| 2009 | 1 |
No forecast is made for this condition: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 2 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Cherubism trials in? (1)
Shown in this order: phase order.
| Phase | Trials |
|---|---|
| Observational | 2 |
How many Cherubism trials are recruiting? (2)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 1 |
| Completed | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which publications cover Cherubism? (9)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Second-Generation SYK Inhibitor Entospletinib Ameliorates Fully Established Inflammation and Bone Destruction in the Cherubism Mouse Model. | Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research | 2018 | Yes |
| Enhanced TLR-MYD88 signaling stimulates autoinflammation in SH3BP2 cherubism mice and defines the etiology of cherubism. | Cell reports | 2014 | Yes |
| The role of SH3BP2 in the pathophysiology of cherubism. | Orphanet journal of rare diseases | 2012 | Yes |
| Cherubism: best clinical practice. | Orphanet journal of rare diseases | 2012 | Yes |
| Loss of Tankyrase-mediated destruction of 3BP2 is the underlying pathogenic mechanism of cherubism. | Cell | 2011 | Yes |
Showing 5 of 9 publications.
Prevalence (6)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Cherubism | Cases families | Worldwide | Not stated | Exact | |
| Cherubism | Point prevalence | <1 / 1 000 000 | Worldwide | Not stated | Unspecified |
| Cherubism | Cases families | Worldwide | Not stated | Unspecified | |
| Cherubism | Point prevalence | <1 / 1 000 000 | Worldwide | Not stated | Exact |
| Cherubism | Point prevalence | <1 / 1 000 000 | Worldwide | Not stated | Exact |
Showing 5 of 6 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Cherubism | 184 | Exact | Orphadata Science knowledge files, Product 1 |
| Cherubism | 184 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: lead sponsors, serious adverse events in this condition's trials, and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.